Guggenheim Maintains Buy on Dyne Therapeutics, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $33 to $37.
March 07, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Debjit Chattopadhyay reaffirms a Buy rating on Dyne Therapeutics and increases the price target to $37.
The upgrade in the price target by a reputable analyst like Debjit Chattopadhyay from Guggenheim is a strong positive signal for Dyne Therapeutics. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100